Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway

NCT00667641 is registered in ClinicalTrials.gov with University of Medicine and Dentistry of New Jersey as lead sponsor.

NCT NCT00667641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway
Lead sponsor
University of Medicine and Dentistry of New Jersey
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
February 28, 2009
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, head and neck cancer, lung cancer, melanoma (skin), ovarian cancer, pancreatic cancer, prostate cancer, unspecified adult solid tumor, protocol specific